Scailyte raises CHF 2.75M in seed funding and gains
Swisscom Ventures & Zürcher Kantonalbank as investors
Scailyte AG, a Swiss startup in the emerging and rapidly growing field of single-cell technologies, raised CHF 2.75M in seed funding and gained Swisscom Ventures as a strategic investor. Zürcher Kantonalbank also joined the financing round, alongside the existing shareholders, thus reaffirming their trust in the competence and vision of Scailyte’s team. Dominique Megret, Head of Swisscom Ventures, will join the Board of Directors of Scailyte, along with Pascal Winnen, CEO of Hemex AG.
Scailyte develops artificial intelligence (AI) based software for best-in-class analysis of complex single-cell data to enhance biomedical research, pharmaceutical discovery and precision diagnostics. The software for biomedical research, commercialized under the brand ScaiVision, will be launched in the beginning of 2019. Scailyte also offers biomarker discovery services to companies aiming to complement and enrich their analysis by adding the single-cell perspective.
The raised capital will be used to enhance the market entry and to speed up further development of ScaiVision, allowing it to be more accessible and attractive to a wider range of customers.
There is a huge potential in the single-cell technologies. Renowned magazine The Scientist has just published this year’s Top 10 Innovations – a ranking done by a panel of Key Opinion Leaders from the life sciences, which features four technologies for single-cell analysis. According to The Scientist, the advantage of capturing these reams of biological information on the level of a single-cell is revealing the variety within tissues not detectable in pooled samples. This may allow scientists to more accurately detect disease specifics.
“The future of healthcare is about detecting and understanding valuable information hidden in complex data patterns.” says Peter Nestorov, CEO of Scailyte AG. “With our AI-based software for single-cell data interpretation, we will accelerate biomedical discovery and enable the next generation of precision diagnostics. With the support of strong partners like Swisscom Ventures and Zürcher Kantonalbank, we will grow to become pioneers and leaders in the fast emerging Single-Cell Analysis market, enabling the clinical application of single-cell data. “
Dominique Megret, Head of Swisscom Ventures, who will join the Board of Directors, explained “Swisscom Ventures invests in software applications based on powerful machine learning algorithms. We believe the single-cell analysis technology will bring precision medicine to the next level. We were impressed by Scailyte’s team, who bring together unique skills from both computational biology and Next-Generation Sequencing device markets. ”
Also joining Scailyte’s Board of Directors will be Pascal Winnen, CEO of Hemex AG, who commented: ”Hemex has supported the development of several innovative therapies and immediately recognized the potential of Scailyte’s technology to unlock “big data” in order to find more precise, personalized cures and even detect diseases before they manifest clinically in patients. We are proud to join Scailyte at the forefront of AI single-cell data analysis.”